Table 2.

Baseline characteristics for patients with F-NLR score in primary and validation cohort

Clinical parameter	Primary cohort				Validation cohort
	F-NLR = 0 (131)	F-NLR = 1 (213)	F-NLR = 2 (115)	P	F-NLR = 0 (33)	F-NLR = 1 (75)	F-NLR = 2 (37)	P
Sex				0.271				0.048*
Male	94	169	87		24	54	34
Female	37	44	28		9	21	3
Age				0.215				0.399
≤ 60	66	93	61		20	40	16
> 60	65	120	54		13	35	21
Tumor location				0.066				0.102
Upper	14	10	7		2	9	3
Middle	72	145	79		25	48	18
Lower	45	58	29		6	18	16
Histological grade				0.071				0.135
Well	11	11	3		0	8	1
Moderately	72	99	54		18	28	17
Poorly	48	103	58		15	39	19
T stage				0.003*				< 0.001*
T1	52	46	27		10	17	2
T2	30	58	24		17	20	2
T3	49	105	61		5	37	33
T4a	0	4	3		1	1	0
N stage				0.429				0.002*
N0	84	120	59		24	41	9
N1	33	56	35		6	22	14
N2	10	29	16		3	9	9
N3	4	8	5		0	3	5
TNM stage (AJCC, 8th)				0.004*				< 0.001*
I	44	41	23		9	12	1
II	55	97	43		18	40	10
III–IVa	32	75	49		6	23	26
Fibrinogen				< 0.001*				< 0.001*
Fib < 3.5 g/L	131	137	0		33	36	0
Fib ≥ 3.5 g/L	0	76	115		0	39	37
NLR				< 0.001*				< 0.001*
NLR < 1.95	131	76	0		33	39	0
NLR ≥ 1.95	0	137	115		0	36	37
PLR				0.001*				< 0.001*
PLR < 130	92	113	57		22	34	6
PLR ≥ 130	39	167	58		11	41	31
MLR				< 0.001*				0.001*
MLR < 0.25	90	86	27		21	28	7
MLR ≥ 0.25	41	127	88		12	47	30

F-NLR: Fibrinogen-neutrophil lymphocyte ratio; NLR: neutrophil lymphocyte ratio; PLR: platelet lymphocyte ratio; MLR: monocyte to lymphocyte ratio